Stifel has initiated Phathom Pharmaceuticals (NASDAQ:PHAT) at buy citing the company's acid-reducing therapy Voquezna (vonoprazan) as a drug that could potentially become a new standard of care. The ...
Source LinkStifel has initiated Phathom Pharmaceuticals (NASDAQ:PHAT) at buy citing the company's acid-reducing therapy Voquezna (vonoprazan) as a drug that could potentially become a new standard of care. The ...
Source Link
Comments